1. Home
  2. LKQ vs NUVL Comparison

LKQ vs NUVL Comparison

Compare LKQ & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LKQ Corporation

LKQ

LKQ Corporation

HOLD

Current Price

$24.56

Market Cap

7.4B

ML Signal

HOLD

Logo Nuvalent Inc.

NUVL

Nuvalent Inc.

HOLD

Current Price

$100.44

Market Cap

8.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LKQ
NUVL
Founded
1998
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Motor Vehicles
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.4B
8.3B
IPO Year
2003
2021

Fundamental Metrics

Financial Performance
Metric
LKQ
NUVL
Price
$24.56
$100.44
Analyst Decision
Buy
Strong Buy
Analyst Count
6
16
Target Price
$42.33
$134.75
AVG Volume (30 Days)
3.1M
499.3K
Earning Date
04-30-2026
05-08-2026
Dividend Yield
3.91%
N/A
EPS Growth
N/A
N/A
EPS
2.35
N/A
Revenue
$13,651,000,000.00
N/A
Revenue This Year
$2.18
N/A
Revenue Next Year
$1.71
$1,239.49
P/E Ratio
$10.52
N/A
Revenue Growth
N/A
N/A
52 Week Low
$24.57
$70.25
52 Week High
$40.94
$113.02

Technical Indicators

Market Signals
Indicator
LKQ
NUVL
Relative Strength Index (RSI) 24.05 43.43
Support Level N/A $97.91
Resistance Level $32.14 $107.72
Average True Range (ATR) 1.21 3.86
MACD -0.53 -0.25
Stochastic Oscillator 2.92 19.66

Price Performance

Historical Comparison
LKQ
NUVL

About LKQ LKQ Corporation

LKQ Corp is a world-wide distributor of vehicle products, including replacement parts, components and systems used in the repair and maintenance of vehicles, and specialty aftermarket products and accessories to improve the performance, functionality and appearance of vehicles. The company is organized into three operating segments: North America; Europe; and Specialty segment. It derives maximum revenue from Europe Segment. Europe segment is a provider of alternative vehicle replacement and maintenance products in Germany, the United Kingdom, the Benelux region (Belgium, Netherlands, and Luxembourg), Italy, Czech Republic, Austria, Slovakia, France and various other European countries.

About NUVL Nuvalent Inc.

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

Share on Social Networks: